Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RISPERDAL vs ABILIFY ASIMTUFII
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors. The active metabolite, dehydro-aripiprazole, contributes to the pharmacological activity. Abilify Asimtufii is a long-acting injectable formulation for intramuscular use.
Schizophrenia (FDA-approved),Bipolar I disorder (acute manic or mixed episodes) (FDA-approved),Irritability associated with autistic disorder (FDA-approved),Treatment-resistant depression (adjunctive to antidepressants) (off-label),Tourette's disorder (off-label),Obsessive-compulsive disorder (adjunctive) (off-label),Post-traumatic stress disorder (off-label),Delirium (off-label)
Schizophrenia,Maintenance monotherapy treatment of bipolar I disorder
2-8 mg orally once daily or divided twice daily; maximum 16 mg/day
Recommended starting dose: 400 mg intramuscularly once monthly, with a single oral dose of 10-20 mg aripiprazole or continued oral therapy for 14 days to ensure tolerability. Maintenance dose: 300-400 mg monthly.
20 hours (parent drug), 23 hours (active metabolite 9-hydroxyrisperidone). Steady state reached in 5-6 days. Extended in elderly and hepatic/renal impairment.
Terminal elimination half-life: 29-40 days (aripiprazole) and 48-63 days (dehydraripiprazole), allowing monthly dosing.
Risperidone is extensively metabolized by cytochrome P450 2D6 (CYP2D6) to its active metabolite, 9-hydroxyrisperidone (paliperidone). A minor pathway involves CYP3A4 and CYP3A5. The metabolite is further metabolized via N-dealkylation and oxidative pathways.
Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole is formed primarily by CYP3A4 and CYP2D6; exhibits significant interindividual variability due to CYP2D6 polymorphism.
Renal: 70% (30% as unchanged drug, 40% as metabolites), Fecal/Biliary: 14%
Renal (approximately 25% unchanged and 55% as metabolites), fecal (approximately 20%).
90% (albumin and alpha-1-acid glycoprotein). Active metabolite 77% bound.
>99% bound to serum albumin.
1-2 L/kg. Large Vd indicates extensive tissue distribution and penetration into CNS.
4.9 L/kg, indicating extensive extravascular distribution.
Oral: 70% (with extensive first-pass metabolism). IM: 100% for immediate-release. Long-acting IM: fraction absorbed over depot injection.
Intramuscular: 100% (as a depot suspension).
Cr Cl <30 m L/min: initial 0.5 mg twice daily, increase by 0.5 mg increments; max 3 mg/day
No dosage adjustment required for patients with renal impairment (Cr Cl ≥15 m L/min). Insufficient data for patients with end-stage renal disease (Cr Cl <15 m L/min).
Child-Pugh class A or B: initial 0.5 mg twice daily, increase by 0.5 mg increments; max 3 mg/day; Child-Pugh C: not studied
No dosage adjustment recommended for mild to moderate hepatic impairment (Child-Pugh class A or B). Use with caution in severe hepatic impairment (Child-Pugh class C) as experience is limited.
13-17 yr: 0.5 mg once daily, titrate by 0.5-1 mg/day at ≥24 hr intervals; target 3 mg/day; max 6 mg/day. 10-12 yr: 0.5 mg once daily, titrate by 0.5 mg/day; target 1-2.5 mg/day; max 3 mg/day
Not approved for use in pediatric patients. Safety and efficacy have not been established.
Initial 0.5 mg twice daily; increase by 0.5 mg increments; max 3 mg/day; monitor for orthostatic hypotension and sedation
Use with caution due to increased sensitivity to orthostatic hypotension and sedative effects. Consider lower starting doses (300 mg orally equivalent) but no specific dose adjustment for the injectable form is recommended.
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of dementia-related psychosis.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Abilify Asimtufii is not approved for the treatment of patients with dementia-related psychosis.
Increased mortality in elderly patients with dementia-related psychosis,Cerebrovascular adverse events (e.g., stroke, transient ischemic attack) in elderly with dementia,Neuroleptic malignant syndrome (NMS),Tardive dyskinesia,Hyperglycemia and diabetes mellitus,Weight gain,Dyslipidemia,Orthostatic hypotension and syncope,Seizures,Leukopenia, neutropenia, and agranulocytosis,QT interval prolongation,Hyperprolactinemia,Body temperature dysregulation,Dysphagia,Priapism,Thrombotic thrombocytopenic purpura (TTP)
Increased mortality in elderly patients with dementia-related psychosis; cerebrovascular adverse events (e.g., stroke, transient ischemic attack) in elderly patients with dementia-related psychosis; neuroleptic malignant syndrome (NMS); tardive dyskinesia; metabolic changes (hyperglycemia/diabetes mellitus, dyslipidemia, weight gain); pathological gambling and other compulsive behaviors; orthostatic hypotension; leukopenia/neutropenia/agranulocytosis; seizures; body temperature dysregulation; dysphagia; potential for additive effects with alcohol or CNS depressants; injection site reactions; risk of extrapyramidal symptoms; suicidal thoughts/behaviors.
Hypersensitivity to risperidone, paliperidone, or any component of the formulation
Known hypersensitivity to aripiprazole or any component of the formulation; concurrent use of strong CYP3A4 inducers (e.g., carbamazepine, rifampin)
Grapefruit juice may increase risperidone levels; avoid concurrent use. Risperidone can be taken with or without food. High-fat meals do not affect absorption. Weight gain is common; encourage heart-healthy diet. Alcohol may exacerbate CNS depression and orthostatic hypotension; advise avoidance.
Avoid grapefruit juice and grapefruit products as they may increase aripiprazole levels. Alcohol should be limited or avoided due to additive CNS depression and increased risk of sedation.
First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Risk of extrapyramidal symptoms and/or withdrawal symptoms in neonates if exposed during third trimester. Overall, not considered a major teratogen.
Pregnancy Category C: First trimester risk of congenital malformations unknown; second/third trimester exposure may cause extrapyramidal and/or withdrawal symptoms in neonates. Advise use only if benefit outweighs risk.
Risperidone and its active metabolite 9-hydroxyrisperidone are excreted in breast milk. Milk-to-plasma ratio (M/P) approximately 0.42-0.44. Relative infant dose is about 4-9% of maternal weight-adjusted dose. Monitor infant for sedation, poor feeding, and extrapyramidal symptoms. Consider benefits of breastfeeding vs. risk.
Excreted in human milk; limited data. M/P ratio not established. Decision to discontinue nursing or drug based on importance of drug to mother. Use caution.
Increased plasma volume and hepatic metabolism may lower risperidone concentrations, especially in second and third trimesters. Dose adjustments may be needed; monitor clinical response and consider therapeutic drug monitoring. No standard dose adjustment recommendation; titrate to effect.
No recommended dose adjustments in pregnancy; consider pharmacokinetic changes (e.g., increased clearance) may require titration, but evidence lacking.
Risperdal (risperidone) is a second-generation antipsychotic with high affinity for D2 and 5-HT2A receptors. Monitor for orthostatic hypotension during dose titration, especially in elderly. QT prolongation risk is dose-dependent; avoid with hypokalemia, hypomagnesemia, or concomitant QT-prolonging drugs. Therapeutic response for psychosis may take 2-4 weeks. For agitation, consider sublingual or IM formulations. Extrapyramidal symptoms are dose-related; more common at doses >6 mg/day. Prolactin elevation is more pronounced than with other atypical antipsychotics; monitor for galactorrhea, gynecomastia, menstrual irregularities. Weight gain and metabolic syndrome require baseline and periodic monitoring of BMI, fasting glucose, and lipids. Risk of tardive dyskinesia with long-term use. In elderly with dementia-related psychosis, increased mortality.
ABILIFY ASIMTUFII (aripiprazole) is a long-acting injectable suspension for intramuscular use. Administer only by a healthcare professional. Observe patient for 2 hours post-injection due to risk of post-injection delirium/sedation syndrome. Requires 3 consecutive daily doses of oral aripiprazole (10-20 mg) before initiation to confirm tolerability. Dosing: 441 mg IM monthly (equates to 400 mg aripiprazole). Do not substitute with other aripiprazole formulations on a mg-per-mg basis. Contraindicated in patients with known hypersensitivity to aripiprazole.
Take risperidone exactly as prescribed; do not crush or chew tablets.,Avoid alcohol and grapefruit juice as they may worsen side effects.,Rise slowly from sitting or lying to prevent dizziness or fainting.,Report unusual muscle stiffness, tremors, or restlessness immediately.,Notify your doctor if you experience breast swelling, discharge, or sexual dysfunction.,Risperidone may cause drowsiness; avoid driving until you know how the drug affects you.,Do not stop abruptly; withdrawal may cause nausea, vomiting, or insomnia.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.,Avoid overheating or dehydration; increased body temperature may occur.
This medication is given as an injection once a month by your healthcare provider.,Do not try to inject yourself; it must be given by a healthcare professional.,After each injection, you will need to stay at the doctor's office or clinic for at least 2 hours to be monitored for any serious side effects.,You will need to take oral aripiprazole for 3 days before your first injection to see if you can tolerate the medication.,Common side effects include headache, insomnia, nausea, and injection site pain.,Seek emergency care if you have allergic reaction (hives, difficulty breathing, swelling), uncontrolled muscle movements, or thoughts of suicide.,Avoid alcohol and grapefruit juice while on this medication.,Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,Do not stop treatment without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RISPERDAL vs ABILIFY ASIMTUFII, answered by our medical review team.
RISPERDAL is a Atypical Antipsychotic that works by Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.. ABILIFY ASIMTUFII is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors. The active metabolite, dehydro-aripiprazole, contributes to the pharmacological activity. Abilify Asimtufii is a long-acting injectable formulation for intramuscular use.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RISPERDAL and ABILIFY ASIMTUFII depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RISPERDAL is: 2-8 mg orally once daily or divided twice daily; maximum 16 mg/day. The standard adult dose of ABILIFY ASIMTUFII is: Recommended starting dose: 400 mg intramuscularly once monthly, with a single oral dose of 10-20 mg aripiprazole or continued oral therapy for 14 days to ensure tolerability. Maintenance dose: 300-400 mg monthly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RISPERDAL and ABILIFY ASIMTUFII in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RISPERDAL is classified as Category C. First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Risk of extrapyramidal symptoms an. ABILIFY ASIMTUFII is classified as Category C. Pregnancy Category C: First trimester risk of congenital malformations unknown; second/third trimester exposure may cause extrapyramidal and/or withdrawal symptoms in neonates. Adv. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.